6-(1-Benzyl-propyl)-4-hydroxy-3-(1-phenyl-propyl)-pyran-2-one

ID: ALA22164

Chembl Id: CHEMBL22164

PubChem CID: 54686718

Max Phase: Preclinical

Molecular Formula: C24H26O3

Molecular Weight: 362.47

Molecule Type: Small molecule

Names and Identifiers

Synonyms: U-96988 | U-96988|CHEMBL22164|PNU-96988|BDBM770|SCHEMBL6173602|U96988|6-(1-benzylpropyl)-4-hydroxy-3-(1-phenylpropyl)pyran-2-one|4-hydroxy-6-(1-phenylbutan-2-yl)-3-(1-phenylpropyl)-2H-pyran-2-one

Canonical SMILES:  CCC(Cc1ccccc1)c1cc(O)c(C(CC)c2ccccc2)c(=O)o1

Standard InChI:  InChI=1S/C24H26O3/c1-3-18(15-17-11-7-5-8-12-17)22-16-21(25)23(24(26)27-22)20(4-2)19-13-9-6-10-14-19/h5-14,16,18,20,25H,3-4,15H2,1-2H3

Standard InChI Key:  HALPINAQGOXQAN-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA22164

   6-(1-Benzylpropyl)-4-hydroxy-3-(1-phenylpropyl)pyran-2-one

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 362.47

Molecular Weight (Monoisotopic): 362.1882

AlogP: 5.62

#Rotatable Bonds: 7

Polar Surface Area: 50.44

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 7.80

CX Basic pKa: ┄

CX LogP: 6.17

CX LogD: 6.02

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.59

Np Likeness Score: 0.41

References

1. Janakiraman MN, Watenpaugh KD, Tomich PK, Chong KT, Turner SR, Tommasi RA, Thaisrivongs S, Strohbach JW..  (1998)  Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.,  8  (10): [PMID:9871742] [10.1016/s0960-894x(98)00197-8]

2. Thaisrivongs S, Janakiraman MN, Chong KT, Tomich PK, Dolak LA, Turner SR, Strohbach JW, Lynn JC, Horng MM, Hinshaw RR, Watenpaugh KD..  (1996)  Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.,  39  (12): [PMID:8691434] [10.1021/jm950888f]

3. Thaisrivongs S, Tomich PK, Watenpaugh KD, Chong KT, Howe WJ, Yang CP, Strohbach JW, Turner SR, McGrath JP, Bohanon MJ..  (1994)  Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.,  37  (20): [PMID:7932546] [10.1021/jm00046a002]

4. Thaisrivongs S, Skulnick HI, Turner SR, Strohbach JW, Tommasi RA, Johnson PD, Aristoff PA, Judge TM, Gammill RB, Morris JK, Romines KR, Chrusciel RA, Hinshaw RR, Chong KT, Tarpley WG, Poppe SM, Slade DE, Lynn JC, Horng MM, Tomich PK, Seest EP, Dolak LA, Howe WJ, Howard GM, Watenpaugh KD..  (1996)  Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.,  39  (22): [PMID:8893827] [10.1021/jm960541s]

5. Hassan MZ, Osman H, Ali MA, Ahsan MJ..  (2016)  Therapeutic potential of coumarins as antiviral agents.,  123  [PMID:27484512] [10.1016/j.ejmech.2016.07.056]

Source

Source(1):

• Scientific Literature